Biogen announced that its mid-stage monoclonal antibody, litifilimab, is showing promise in reducing joint pain related to systemic lupus erythematosus (SLE) lupus.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,